{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:25Z","timestamp":1791081985745,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1124\/jpet.111.187385","type":"journal-article","created":{"date-parts":[[2012,1,8]],"date-time":"2012-01-08T01:24:11Z","timestamp":1325985851000},"page":"104-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Interferon-\u03b3 Activates Transglutaminase 2 via a Phosphatidylinositol-3-Kinase-Dependent Pathway: Implications for Celiac Sprue Therapy"],"prefix":"10.1016","volume":"341","author":[{"given":"Thomas R.","family":"DiRaimondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Kl\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitan","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.187385_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-immunol-040210-092915","article-title":"Integration of genetic and immunological insights into a model of celiac disease pathogenesis","volume":"29","author":"Abadie","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/jpet.111.187385_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08916930701619219","article-title":"Autoantibodies in celiac disease","volume":"41","author":"Alaedini","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1124\/jpet.111.187385_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/73200","article-title":"In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope","volume":"6","author":"Anderson","year":"2000","journal-title":"Nat Med"},{"key":"10.1124\/jpet.111.187385_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jir.2008.0057","article-title":"Interferon-\u03b3 regulation of intestinal epithelial permeability","volume":"29","author":"Beaurepaire","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1124\/jpet.111.187385_bib5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.chembiol.2009.07.009","article-title":"Noninflammatory gluten peptide analogs as biomarkers for celiac sprue","volume":"16","author":"Bethune","year":"2009","journal-title":"Chem Biol"},{"key":"10.1124\/jpet.111.187385_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.108.148007","article-title":"Interferon-\u03b3 released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides","volume":"329","author":"Bethune","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187385_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.dld.2006.05.021","article-title":"Transglutaminase 2 in the enterocytes is coeliac specific and gluten dependent","volume":"38","author":"Biagi","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1124\/jpet.111.187385_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gut.25.2.145","article-title":"In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease","volume":"25","author":"Bjarnason","year":"1984","journal-title":"Gut"},{"key":"10.1124\/jpet.111.187385_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2008.0128","article-title":"Mechanism of interferon-\u03b3-induced increase in T84 intestinal epithelial tight junction","volume":"29","author":"Boivin","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1124\/jpet.111.187385_bib10","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.4049\/jimmunol.171.11.6164","article-title":"Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms","volume":"171","author":"Bruewer","year":"2003","journal-title":"J Immunol"},{"key":"10.1124\/jpet.111.187385_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1096\/fj.04-3260com","article-title":"Interferon-\u03b3 induces internalization of epithelial tight junction proteins via a macropinocytosis-like process","volume":"19","author":"Bruewer","year":"2005","journal-title":"FASEB J"},{"issue":"Suppl","key":"10.1124\/jpet.111.187385_bib12","first-page":"122s","article-title":"Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors","volume":"27","author":"Chiorean","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.111.187385_bib13","doi-asserted-by":"crossref","first-page":"27399","DOI":"10.1074\/jbc.M403530200","article-title":"A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C\u03b5, and MAPK in mesangial cells regulates interferon-\u03b3-induced STAT1 transcriptional activation","volume":"279","author":"Choudhury","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.187385_bib14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/gut.2010.209395","article-title":"Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease?","volume":"59","author":"De Re","year":"2010","journal-title":"Gut"},{"key":"10.1124\/jpet.111.187385_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1651-2227.1953.tb05563.x","article-title":"Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease","volume":"42","author":"Dicke","year":"1953","journal-title":"Acta Paediatr"},{"key":"10.1124\/jpet.111.187385_bib16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/j.1572-0241.2003.07582.x","article-title":"Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease","volume":"98","author":"Esposito","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/jpet.111.187385_bib17","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187385_bib18","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"10.1124\/jpet.111.187385_bib19","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMra071600","article-title":"Celiac disease","volume":"357","author":"Green","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.111.187385_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.57.051804.122404","article-title":"Celiac disease","volume":"57","author":"Green","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1124\/jpet.111.187385_bib21","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.bmc.2006.06.046","article-title":"Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors","volume":"14","author":"Hayakawa","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.111.187385_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","article-title":"PI 3-kinase p110\u03b2: a new target for antithrombotic therapy","volume":"11","author":"Jackson","year":"2005","journal-title":"Nat Med"},{"key":"10.1124\/jpet.111.187385_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.0105-2896.2005.00294.x","article-title":"Innate and adaptive immunity: the yin and yang of celiac disease","volume":"206","author":"Jabri","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.111.187385_bib24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nri2670","article-title":"Tissue-mediated control of immunopathology in coeliac disease","volume":"9","author":"Jabri","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/jpet.111.187385_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI30253","article-title":"Celiac disease: pathogenesis of a model immunogenetic disease","volume":"117","author":"Kagnoff","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.187385_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0198-8859(03)00027-2","article-title":"HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease","volume":"64","author":"Karell","year":"2003","journal-title":"Hum Immunol"},{"key":"10.1124\/jpet.111.187385_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.str.2004.01.005","article-title":"Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1","volume":"12","author":"Komander","year":"2004","journal-title":"Structure"},{"key":"10.1124\/jpet.111.187385_bib28","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/092986709788803222","article-title":"Advances in development of phosphatidylinositol 3-kinase inhibitors","volume":"16","author":"Kong","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.111.187385_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/gut.2009.183608","article-title":"Lysosomal accumulation of gliadin p31\u201343 peptide induces oxidative stress and tissue transglutaminase-mediated PPAR\u03b3 downregulation in intestinal epithelial cells and coeliac mucosa","volume":"59","author":"Luciani","year":"2010","journal-title":"Gut"},{"key":"10.1124\/jpet.111.187385_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI113938","article-title":"Interferon-\u03b3 directly affects barrier function of cultured intestinal epithelial monolayers","volume":"83","author":"Madara","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.187385_bib31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.111.187385_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/jpet.106.113639","article-title":"Phosphatidylinositol 3\u2032-kinase is a critical mediator of interferon-\u03b3-induced increases in enteric epithelial permeability","volume":"320","author":"McKay","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187385_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm0698-713","article-title":"Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease","volume":"4","author":"Molberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1124\/jpet.111.187385_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.immuni.2010.03.001","article-title":"Interferon-\u03b3 regulates intestinal epithelial homeostasis through converging \u03b2-catenin signaling pathways","volume":"32","author":"Nava","year":"2010","journal-title":"Immunity"},{"key":"10.1124\/jpet.111.187385_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0016-5085(98)70134-9","article-title":"Gluten induces an intestinal cytokine response strongly dominated by interferon \u03b3 in patients with celiac disease","volume":"115","author":"Nilsen","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.111.187385_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gut.37.6.766","article-title":"Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon \u03b3","volume":"37","author":"Nilsen","year":"1995","journal-title":"Gut"},{"key":"10.1124\/jpet.111.187385_bib37","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1073\/pnas.91.5.1942","article-title":"Intestinal absorption and excretion of octapeptides composed of D amino acids","volume":"91","author":"Pappenheimer","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.187385_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0022-3565(24)36388-8","article-title":"Absorption and excretion of undegradable peptides: role of lipid solubility and net charge","volume":"280","author":"Pappenheimer","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187385_bib39","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1021\/jm0601598","article-title":"Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase \u03b3","volume":"49","author":"Pomel","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187385_bib40","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.4049\/jimmunol.170.5.2647","article-title":"Essential role of phosphoinositide 3-kinase \u0394 in neutrophil directional movement","volume":"170","author":"Sadhu","year":"2003","journal-title":"J Immunol"},{"key":"10.1124\/jpet.111.187385_bib41","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1091\/mbc.e07-04-0315","article-title":"Rho\/Rho-associated kinase-II signaling mediates disassembly of epithelila apical junctions","volume":"18","author":"Samarin","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1124\/jpet.111.187385_bib42","doi-asserted-by":"crossref","first-page":"27952","DOI":"10.1074\/jbc.M109.046292","article-title":"AMP-activated protein kinase mediates the interferon-\u03b3-induced decrease in intestinal epithelial barrier function","volume":"284","author":"Scharl","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.187385_bib43","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1126\/science.1074129","article-title":"Structural basis for gluten intolerance in celiac sprue","volume":"297","author":"Shan","year":"2002","journal-title":"Science"},{"key":"10.1124\/jpet.111.187385_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.05.003","article-title":"Transglutaminase 2 inhibitors and their therapeutic role in disease states","volume":"115","author":"Siegel","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.111.187385_bib45","doi-asserted-by":"crossref","first-page":"e1861","DOI":"10.1371\/journal.pone.0001861","article-title":"Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury","volume":"3","author":"Siegel","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1124\/jpet.111.187385_bib46","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0016-5085(97)70123-9","article-title":"Gastrointestinal permeability in celiac disease","volume":"112","author":"Smecuol","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.111.187385_bib47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2796.2011.02376.x","article-title":"Novel therapies for coeliac disease","volume":"269","author":"Sollid","year":"2011","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.111.187385_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.169.1.345","article-title":"Evidence for a primary association of celiac disease to a particular HLA-DQ \u03b1\/\u03b2 heterodimer","volume":"169","author":"Sollid","year":"1989","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.111.187385_bib49","doi-asserted-by":"crossref","first-page":"C649","DOI":"10.1152\/ajpcell.2001.281.2.C649","article-title":"Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms","volume":"281","author":"Song","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/jpet.111.187385_bib50","doi-asserted-by":"crossref","first-page":"25402","DOI":"10.1074\/jbc.M109.097162","article-title":"Redox regulation of transglutaminase 2 activity","volume":"285","author":"Stamnaes","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.187385_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbapap.2005.06.015","article-title":"Development of specific Rho-kinase inhibitors and their clinical application","volume":"1754","author":"Tamura","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.111.187385_bib52","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1091\/mbc.e05-03-0193","article-title":"Mechanism of IFN-\u03b3-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane","volume":"16","author":"Utech","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1124\/jpet.111.187385_bib53","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.161.4.1585","article-title":"Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity","volume":"161","author":"van de Wal","year":"1998","journal-title":"J Immunol"},{"key":"10.1124\/jpet.111.187385_bib54","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","article-title":"A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1benzopyran-4-one (LY294002)","volume":"269","author":"Vlahos","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.187385_bib55","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1021\/jm060839a","article-title":"Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles","volume":"49","author":"Watts","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187385_bib56","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/ja056423o","article-title":"Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from \u03b12-gliadin","volume":"128","author":"Xia","year":"2006","journal-title":"J Am Chem Soc"},{"key":"10.1124\/jpet.111.187385_bib57","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1158\/0008-5472.CAN-04-0343","article-title":"Akt\/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cell overexpressing Akt","volume":"64","author":"Yang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.111.187385_bib58","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.187385_bib59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/gast.2002.34235","article-title":"A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease","volume":"123","author":"Zolotarevsky","year":"2002","journal-title":"Gastroenterology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652418144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652418144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.187385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:43:58Z","timestamp":1739983438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652418144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S002235652418144X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.187385","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b3 Activates Transglutaminase 2 via a Phosphatidylinositol-3-Kinase-Dependent Pathway: Implications for Celiac Sprue Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.187385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}